On December 5, 2024, David O'Toole, Chief Financial Officer of AVITA Medical Inc, purchased 975 shares of the company (RCEL, Financial). Following this transaction, the insider now holds a total of 23,734 shares. The purchase was documented in an SEC Filing.
AVITA Medical Inc (RCEL) is a regenerative medicine company focused on the development and commercialization of innovative therapies for the treatment of burns, chronic wounds, and other skin defects. The company's proprietary technology platform, RECELL System, is designed to harness the regenerative properties of a patient's own skin to facilitate healing.
The insider's recent acquisition is part of a broader trend observed over the past year, where David O'Toole has purchased a total of 4,175 shares, with no recorded sales. In the same period, AVITA Medical Inc has seen a total of four insider buys and three insider sells.
On the day of the insider's recent purchase, shares of AVITA Medical Inc were trading at $12.46, giving the company a market cap of $326.147 million. The stock's GF Value is estimated at $16.03, resulting in a price-to-GF-Value ratio of 0.78, indicating that the stock is modestly undervalued according to its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also considers a GuruFocus adjustment factor based on the company’s past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
